Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Watch Dopesick on Disney Plus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 04, 2023 1:46am
369 Views
Post# 35202052

RE:RE:RE:Watch Dopesick on Disney Plus

RE:RE:RE:Watch Dopesick on Disney PlusExactly right Bagger ...

It takes a few listens to really get all the details.

One comment that Dan made that really got me thinking was ... lots of H2S learning over the past 3 years which adds to our understanding and intelectual property.

That comment may relate directly to the improved understanding of our drug, how it affect the liver - and - the move to amorphous OTENA ... but ... there's a lot more work being done in unrelated studies that just might show even greater superiority.

For example, studies like ... anit-inflammatory drugs may cause chronic pain in RA

and ...

studies like ... Opioids nearly double risk for venous thromboembolism vs. NSAIDs

also ...

investigations into ... Common anti-inflammatories my be ruining kids teeth


All seem to be playing into the hope that OTENA just might be better than other anti-inflammatory drugs.

If H2S is the body's manager of inflammation and if it provides cellular protection and cellular repair,  to what extent does H2S reverse some of these other unwanted effects ?

Time will tell if we truly are better and exactly how much better.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities